Results 31 to 40 of about 798,481 (288)
The novel mTOR inhibitor RAD001 (Everolimus) induces antiproliferative effects in human pancreatic neuroendocrine tumor cells [PDF]
, 2007 Background/Aim: Tumors exhibiting constitutively activated PI(3) K/Akt/mTOR signaling are hypersensitive to mTOR inhibitors such as RAD001 (everolimus) which is presently being investigated in clinical phase II trials in various tumor entities, including
Brand, Stephan +8 more
core +1 more source
Resistance to mTOR kinase inhibitors in lymphoma cells lacking 4EBP1.
PLoS ONE, 2014 Inhibitors of the mechanistic target of rapamycin (mTOR) hold promise for treatment of hematological malignancies. Analogs of the allosteric mTOR inhibitor rapamycin are approved for mantle cell lymphoma but have limited efficacy in other blood cancers ...
Sharmila Mallya +5 more
doaj +1 more source
Deptor: not only a mTOR inhibitor [PDF]
Journal of Experimental & Clinical Cancer Research, 2017 Deptor is an important protein that belongs to the mTORC1 and mTORC2 complexes, able to interact with mTOR and to inhibit its kinase activity. As a natural mTOR inhibitor, Deptor is involved in several molecular pathways, such as cell growth, apoptosis, autophagy and ER stress response.
Catena, Valeria, Fanciulli, Maurizio
openaire +2 more sources
Journal of Ophthalmology, 2011 Novel therapeutics such as inhibitors of PI3K/Akt/mTOR pathway presents a unique opportunity for the management of diabetic retinopathy (DR). Second generation mTOR inhibitors have the prospect to be efficacious in managing various stages of disease ...
Jorge L. Jacot, David Sherris
doaj +1 more source
PI3K/AKT/mTOR-Targeted Therapy for Breast Cancer
Cells, 2022 Phosphatidylinositol 3-kinase (PI3K), protein kinase B (PKB/AKT) and mechanistic target of rapamycin (mTOR) (PAM) pathways play important roles in breast tumorigenesis and confer worse prognosis in breast cancer patients.
Kunrui Zhu +6 more
doaj +1 more source
Rapamycin and mTOR kinase inhibitors [PDF]
Journal of Chemical Biology, 2008 Mammalian target of rapamycin (mTOR) is a protein kinase that controls cell growth, proliferation, and survival. mTOR signaling is often upregulated in cancer and there is great interest in developing drugs that target this enzyme. Rapamycin and its analogs bind to a domain separate from the catalytic site to block a subset of mTOR functions.
Lisa M, Ballou, Richard Z, Lin
openaire +2 more sources
Quantitative phosphoproteomics reveal that mTOR regulates cell growth and proliferation by phosphorylating a functionally diverse set of substrates [PDF]
, 2012 The atypical Ser/Thr kinase target of rapamycin (TOR) is a central controller of cell growth and proliferation. TOR forms two distinct multiprotein complexes, TORC1 and TORC2, which are structurally and functionally conserved from yeast to humans.
Robitaille, Aaron M.
core +1 more source
SLAS Technology, 2023 Autosomal dominant polycystic kidney disease (ADPKD) is the most common genetic kidney disease and is characterized by the formation of renal cysts and the eventual development of end-stage kidney disease.
Alysia Cox +4 more
doaj +1 more source
Development of novel, potent and selective small molecular weight PI3K/mTOR inhibitors for the treatment of cancer [PDF]
, 2011 The phosphoinositide 3-kinases (PI3Ks) belong to a family of lipid kinases, which are implicated in signal transduction pathways and modulation of fundamental cellular activities such as cell growth, proliferation, differentiation, motility, survival and
Cmiljanović, Nataša
core +1 more source
GSK3-mediated raptor phosphorylation supports amino acid-dependent Q2 mTORC1-directed signalling [PDF]
, 2015 The mammalian or mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) is a ubiquitously expressed multimeric protein kinase complex that integrates nutrient and growth factor signals for the co-ordinated regulation of cellular metabolism and cell ...
Stretton, Clare +6 more
core +1 more source